Kristine Ball
Director/Board Member at ATRECA, INC.
Net worth: - $ as of 31/03/2024
Profile
Kristine McClintock Ball is currently the Chief Executive Officer at Antiva Biosciences, Inc. and also holds the position of Chief Executive Officer & Director at Soteria Biotherapeutics, Inc. She is an Independent Director at Atreca, Inc. and a Director at the National Kidney Foundation of Northern California.
Previously, Dr. Ball served as the Chief Executive Officer & Director at Soteria Biotherapeutics, Inc. She was an Independent Director at Forty Seven, Inc. from 2018 to 2020.
She also worked as a Senior Manager at Ernst & Young LLP from 1998 to 2000 and as the Vice President-Finance at Exelixis, Inc. from 2000 to 2005.
Additionally, she held the position of CFO, Senior VP-Administration & Finance at KAI Pharmaceuticals, Inc. From 2017 to 2020, Dr. Ball served as the Chief Financial Officer & SVP-Corporate Strategy at Menlo Therapeutics, Inc. She was also the Chief Financial Officer & Senior Vice President at Relypsa, Inc. from 2012 to 2016.
Dr. Ball completed her undergraduate degree at Babson College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ATRECA, INC. CLASS A
-.--% | 13/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Kristine Ball active positions
| Companies | Position | Start |
|---|---|---|
| ATRECA, INC. | Director/Board Member | 20/05/2020 |
Antiva Biosciences, Inc.
 Antiva Biosciences, Inc. BiotechnologyHealth Technology Antiva Biosciences, Inc. is a biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. The company was founded by Karl Y. Hostetler in 2012 and is headquartered in South San Francisco, CA. | Chief Executive Officer | 27/04/2023 |
Former positions of Kristine Ball
| Companies | Position | End |
|---|---|---|
| FORTY SEVEN, INC. | Director/Board Member | 07/04/2020 |
| VYNE THERAPEUTICS INC. | Director of Finance/CFO | 01/03/2020 |
| RELYPSA INC | Director of Finance/CFO | 01/01/2016 |
| EXELIXIS, INC. | Director of Finance/CFO | 01/01/2005 |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2000 |
Training of Kristine Ball
| Babson College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| ATRECA, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
KAI Pharmaceuticals, Inc.
 KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Menlo Therapeutics, Inc.
 Menlo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Bridgewater, CA. | Health Technology |
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Antiva Biosciences, Inc.
Antiva Biosciences, Inc. BiotechnologyHealth Technology Antiva Biosciences, Inc. is a biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. The company was founded by Karl Y. Hostetler in 2012 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Kristine Ball
